Table 1. Patient demographics and clinical description (training set n=60, validation set n=179).
| Characteristic | Training set N=60 (%) | Validation set N=179 (%) |
|---|---|---|
|
Age (years, median) (range) |
61 (33–86) |
73 (30–98) |
|
Gender | ||
| Male | 31 (52) | 128 (72) |
| Female |
29 (48) |
51 (28) |
|
Type of histology | ||
| Adenocarcinoma | 31 (52) | 71 (40) |
| Carcinoma, unspecified | 22 (37) | 83 (46) |
| Squamous | 5 (8) | 6 (0.03) |
| Neuroendocrine |
2 (3) |
12 (1) |
|
Specific CUP subtype | ||
| Primary peritoneal | 4 (7) | 0 (0) |
| Adenocarcinoma of axillary glands | 0 (0) | 0 (0) |
| Squamous carcinoma of cervical glands | 1 (2) | 0 (0) |
| Neuroendocrine | 2 (3) | 12 (1) |
| CUP of single location |
1 (2) |
0 (0) |
|
Non-specific subset | ||
| Favourable prognosis | 8 (13) | 42 (23) |
| Poor prognosis |
33 (55) |
125 (70) |
|
Site of metastatic disease | ||
| Liver | 27 (45) | 80 (45) |
| Lung | 15 (25) | 80 (45) |
| Bone | 8 (13) | 74 (41) |
| Lymph node | 35 (58) | 0 (0) |
| CNS |
1 (2) |
0 (0) |
|
Treatment | ||
| Surgery | 9 (15) | 0 |
| Chemotherapy | 56 (93) | 118 (66) |
| Radiotherapy |
10 (17) |
84 (47) |
|
Performance status | ||
| 0 | 12 (20) | 19 (1) |
| 1 | 17 (28) | 67 (37) |
| ⩾2 |
31 (52) |
94 (52) |
|
Median overall survival | ||
| Months, median (range) | 5.9 (0.7–42.9) | 6.2 (0.0–64.3) |
Abbreviations: CNS=central nervous system; CUP=carcinoma of unknown primary.